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Summary Preoperative staging of gastric cancer is difficult. Several molecular markers associated with
initiation and progression of cancer seem promising for obtaining preoperative prognostic information. To
investigate whether these markers are indicative especially for the presence of lymph node metastases in
patients with gastric cancer, we have examined primary tumour specimens from 105 patients with primary
adenocarcinoma of the stomach entered in a surgical trial. In this trial, lymph node status was determined by
strictly quality-controlled lymph node dissection and examination. The selected markers were growth regulators
(p53, Rb and myc), metastasis-suppressor gene product (nm23), adhesion molecules (Ep-CAM, E-cadherin,
CD44v5 and CD44v6) and urokinase-type plasminogen activator (u-PA). Also, the amount of eosinophilic and
lymphocytic infiltrates available post-operatively was analysed with respect to its prognostic value for lymph
node status. Moreover, the association of these parameters with survival and disease-free period (DFP) was
evaluated. Of all molecular markers investigated, only Rb expression had a significant association with the
presence of lymph node metastasis in both univariate and multivariate analysis. For curative resectability, a
significant association was found with Rb and E-cadherin expression, while in multivariate analysis Rb and
myc were selected as the combination with additional independent prognostic value, and E-cadherin had no
additional independent value. For overall survival in univariate analysis, the amount of both eosinophilic and
lymphocytic infiltrates and Rb and myc expression were of significant prognostic value. Only the amount of
lymphocytic infiltrate had a prognostic significance for DFP. In stepwise multivariate analysis, TNM stage
(I+II) and marked lymphocytic infiltrate were associated with better overall survival and longer DFP. We
conclude that, if these results are confirmed in a larger series of patients, molecular markers can provide useful
prognostic information.
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Despite declining incidence, gastric cancer remains a major
clinical management problem with poor prognosis: overall 5
year survival rates vary between 5% and 11%. Only a
curative resection (complete tumour removal) offers hope of a
cure, but the majority of the patients are diagnosed at an
advanced disease stage (Allum et al., 1989). At diagnosis, the
first decision to be made is whether or not to attempt a
curative resection. This decision is based on stage of disease,
which is assessed by radiograph of the stomach, chest and
ultrasound of the liver or computerised tomography (CT)
scan of the abdomen. Palliative resections offer no survival
advantage and are associated with higher operative mortality
rates compared with curative resections (Allum et al., 1989;
Akoh et al., 1991; Wanebo et al., 1993). Laparoscopy and
cytological examination of abdominal washings increase the
accuracy of preoperative staging, but are not used routinely
(Bonenkamp et al., 1996). Therefore, there is a need for
additional, reliable prognostic factors by which tumour
aggressiveness can be determined, and the presence of lymph
node metastasis and resectability for cure can be predicted,
preferably by analysis of biopsy specimens. This would allow
better selection of patients suitable for surgery.
A variety of genetic changes are implicated in the process
of carcinogenesis and the development of metastasis. These
changes are associated with altered expression of proteins,
which were reported to be of prognostic significance in
different types of malignancies, including gastric cancer.
However, not all of these tumour markers have been
analysed in the same specimens and it is not known whether
some of these markers are superior to others or whether a
combination of several markers has a better predictive value
with respect to the presence of lymph node metastasis. As
prognostic tumour markers, proteins known to be associated
with different steps of carcinogenesis (growth promotion, loss
of adhesion, invasion of gastric wall and vessels and distant
metastasis) were analysed.
Our first aim was to study the association between the
absence or presence of expression of these tumour markers
and lymph node status. In addition, the results were also
related to powerful clinicopathological prognostic factors,
such as infiltration depth (T stage), TNM stage and curative
resectability. Staging and curative resectability can be
assessed reliably pre- and post-operatively only and are,
therefore, of no use for patient selection for surgery.
A second aim was to study the prognostic value of these
markers in addition to parameters only determinable post-
operatively (eosinophilic and lymphocytic infiltrates) for
survival and disease-free period (DFP).
Patients and methods
Patients
Between August 1989 and July 1993 a randomised, controlled
multicentre trial was conducted in The Netherlands (Dutch
Gastric Cancer Trial, DGCT) to compare the therapeutic
efficacy of extended lymph node dissection (NI and N2 levels,
so-called D2) with that of limited lymph node dissection (N1
level, so-called D1) in gastric cancer patients operated on with
curative intent. In this trial 1078 patients were entered, 996 of
whom met the eligibility criteria. Strict quality control
measures were taken to obtain optimum lymph node retrieval
and, thus, post-operative staging. In patients undergoing a
curative resection, the presence of nodal involvement was
assessed histologically and the actual number and location of
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the lymph nodes retrieved were recorded by the pathologist.
Criteria for curative resectability were published earlier
(Bonenkamp et al., 1995). Median follow-up of the patients
was 1287 days (range 672-2076 days). In the present study,
tumour tissue of all patients (n = 105) from six randomly
selected hospitals out of the 78 participating hospitals was
analysed. With respect to nodal involvement, only the presence
or absence of nodal involvement was considered, and no
attention was paid to the actual number or location of the
dissected and involved lymph nodes. In 11 patients, no
assessment of the nodal status was performed, because of
locally advanced disease with invasion of adjacent organs, in
which case a surgical resection was not possible and assessment
of nodal status did not have immediate consequences for the
patient. The primary tumour in resection specimens (available
from 81 patients) was scored by one ofthe authors (JHJMvK)
for the amount of lymphocytic and eosinophilic infiltration
(Iwasaki et al., 1986; Pretlow et al., 1983; Jass, 1992).
Tissue specimens and immunohistochemistry
In order to study protein expression in primary adenocarci-
nomas of the stomach, formalin-fixed, paraffin-embedded
tissue blocks of the primary tumour were used. According to
the allocated treatment, the specimens were obtained by DI
or D2 resection. If resection was not possible, the specimen
was obtained by biopsy of the primary tumour. All cases
were reviewed and the tissue block with the largest tumour
diameter was used to cut the required number of sections.
For practical reasons, this was considered representative for
the whole tumour.
Sections (4 ,um thick) were cut, mounted on precoated
slides and kept at 37°C overnight. The sections were dewaxed
in xylol for 20 min and endogenous peroxidase activity was
blocked by methanol/hydrogen peroxide.
The antibodies used were p53 (mAb NCL-p53-DO7,
Novocastra Laboratories), Rb (NCL-RB, retinoblastoma
gene protein clone 1F8, Novocastra Laboratories), myc
(NCL-cMYC, human c-myc protein clone 9E11, Novocastra
Laboratories), nm23 (CRB-nm23 Hl, H2, CRB), Ep-CAM
(323/A3), Centocor, Malvern, PA, USA), E-cadherin (anti-E-
cadherin clone HECD-1, Zymed Laboratories), CD44v5 and
v6 (monoclonal antibodies VFF8 and VFF18 against CD44
variants containing splice variants vS and v6 respectively,
Bender, Vienna, Austria) and urokinase-type plasminogen
activator (u-PA), a proteolytic factor (human urokinase
monoclonal antibody against B-chain, American Diagnostica).
For p53, Rb, E-cadherin and CD44 splice variants, the
sections were first boiled in citrate buffer (pH 6.0) for 25 min.
For myc and Ep-CAM the sections were pretreated with
trypsin (0.1% trypsin with 0.1% calcium chloride) pH 7.4 at
37°C for 20 min. Normal goat serum was applied to reduce
non-specific antibody binding. The primary antibody was
then applied and incubated overnight in its optimum
dilutions in phosphate-buffered saline (PBS)/1% bovine
serum albumin (BSA). The optimum dilutions for primary
antibodies mentioned are summarised in Table I.
For E-cadherin, a double-step detection system was used:
biotinylated rabbit anti-mouse IgG was followed by the
streptavidin-biotin complex (each incubation 45 min). For
the remaining monoclonal antibodies (Rb, myc, Ep-CAM
and p53), a secondary antibody rabbit anti-mouse (RAM)
was followed by a tertiary antibody swine anti-rabbit
(SWAR). Nm23 (polyclonal antibody) was preincubated
with normal goat serum for 10 min before applying SWAR.
In negative controls the primary antibody was replaced by
PBS. The sections were stained with 3-amino-9-ethylcarbazole
(AEC) in dimethylformamide with hydrogen peroxide and
counterstained with Mayer's haematoxylin.
Assessment and statistical analysis of marker expression
Expression of all proteins, except u-PA, was scored as present
()50% of the tumour cells positive) or absent (<50% of the
tumour cell positive). u-PA expression was scored separately
for proportion (1, <25%; 2, 25-49%; 3, 50-75% or 4,
>75%) and intensity (0, none; 1, weak; 2, moderate or 3,
strong). If the proportion was <25% and the intensity was
zero, expression was considered negative; all other combina-
tions were considered positive. Eosinophilic and lymphocytic
infiltration was scored semiquantitatively (1, no or few; 2,
moderate or 3, marked) according to the density of stromal
infiltrate at the advancing front of the tumour.
All specimens were scored by two independent investiga-
tors. In case of disagreement, agreement was obtained by
revision of the specimen by both investigators by means of a
double-headed microscope. Scoring of protein expression was
made without knowledge of the pathological or clinical
outcome of the patients.
For statistical analysis the SPSS program was used. The
chi-square test (with Yates' correction) was used to evaluate
differences in proportions. Step-wise logistic regression
analysis was used to study the prognostic value of tumour
marker combinations for lymph node metastasis. Survival
curves are compared using the log-rank test. Multivariate
survival analysis was performed using Cox's regression
analysis. For the evaluation of overall survival and disease-
free period, post-operative deaths were excluded. Differences
are considered statistically significant when P<0.05.
Results
The results are based on the data of 105 patients, 70 males
and 35 females. Mean age of the patients was 64.9 years (s.d.
10.8) in men and 68.4 years (s.d. 11.9) in women (NS).
The association between positive protein expression and
different tumour characteristics is reported in Tables II and
III. Rb was the only marker with a significant association
with metastatic/unresectable tumours (P =0.006). Myc, nm23,
E-cadherin and u-PA expression were all associated with T
stage (P<0.05). No association was found between protein
expression and TNM stage or tumour location (not shown).
There was also a statistically significant association between
intent of surgery (curative or palliative) and Rb and E-
cadherin expression (P<0.001 and P=0.03).
Step-wise logistic regression analysis was used to
investigate whether a combination of several markers has a
stronger relation with the tumour characteristics than each
marker separately. Also, in multivariate analysis, positive Rb
expression was the only important predictor (RR 3.66; 95%
CI 1.50-8.95; P =0.004) for metastatic or unresectable
tumours. For the risk of the operation being palliative, Rb
(RR 6.47, 95% CI 2.29-18.32, P=0.0003) and myc (RR
0.24, 95% CI 0.08-0.69, P=0.007) were selected as the
combination with additional independent prognostic value.
Table I Antibodies with the dilutions used, staining pattern,
number of specimen examined and percentage of positive expression
in primary adenocarcinmas of the stomach
Specimen
Staining Examined Positive
Markers Dilution pattern n (%)
Growth regulation
p53 1:100 Nuclear 101 39
Rb 1:500 Nuclear 105 53
myc 1:200 Nuclear/ 105 41
cytoplasmic
Adhesion
nm23 1:100 Cytoplasmic 105 50
Ep-CAM 1:100 Membranous 105 58
E-Cadherin 1:1000 Membranous 104 66
CD44v5 1:20 000 Membranous 93 28
CD44v6 1:5000 Membranous 76 90
Plasminogen activation
u-PA 1:100 Cytoplasmic 84 39Prognostic factors in gastric cancer
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Table IV summarises the results of the comparison
(univariate analysis) of marker expression and the amount
of eosinophilic and lymphocyctic infiltration with overall
survival and DFP after curative resection. There was an
association between the amount of eosinophilic and
lymphocytic infiltration, Rb and myc expression and overall
survival, whereas only the presence of moderate-marked
lymphocytic infiltration was associated with DFP. For overall
survival and DFP, multivariate analysis was performed using
the step-wise Cox's regression analysis. If only the markers
that could be determined preoperatively were used, no other
marker had an independent additional value next to Rb
expression for survival. For both overall survival and DFP,
TNM stage and the amount of lymphocytic infiltrate were
selected as the combination with additional independent
prognostic value (Table V).
Discussion
Preoperative staging of gastric cancer is suboptimal. While
the best prognostic information is provided by the TNM
classification, which also determines curative resectability, it
Table II Univariative analysis of the association between lymph
node metastasis and positive marker expression (n= 105) and
lymphocytic and eosinophilic infiltrates (n=81) in primary adeno-
carcinomas of the stomach
Node positivel
Node negative irresectable
Positive Positive
n (%) n (%) P-value
Markers
p53 34 12 (35) 67 27 (40) 0.79
Rb 34 11 (32) 71 45 (63) 0.006
myc 34 16 (47) 71 27 (38) 0.50
nm23 34 17 (50) 71 35 (49) 1.00
Ep-CAM 34 19 (56) 71 42 (59) 0.92
E-cad 34 19 (56) 70 50 (71) 0.18
CD44v5 33 7 (21) 60 19 (32) 0.40
CD44v6 28 24 (86) 48 44 (92) 0.67
u-PA 27 8 (30) 57 25 (44) 0.31
Infiltrates
Lymphocytic 32 49
No or few 7 (22) 16 (33)
Moderate 12 (38) 23 (47) 0.14
Marked 13 (41) 10 (20)
Eosinophilic 32 49
No or few 15 (47) 37 (76)
Moderate 8 (25) 6 (12) 0.03
Marked 9 (28) 6 (12)
can be obtained post-operatively only. Although at present
more accurate staging is possible by means of laparoscopy
and cytological examination of abdominal washings, it is not
routinely used (Bonenkamp et al., 1996). Therefore, there is
still a need for additional, reliable prognostic factors,
preferably obtained by means of minimally invasive
techniques, such as biopsy specimen. Better preoperative
staging or other prognostic factors would be helpful in
selecting patients suitable for surgery and preventing
laparotomy with associated morbidity and mortality in
patients with unresectable (incurable) tumours and would
enable us to predict tumour behaviour and patient prognosis.
The presence of moderate to marked eosinophilic
infiltration was found in gastric (Iwasaki et al., 1986; Yu et
al., 1995) and human colonic cancer (Pretlow et al., 1983) to
be associated with prolonged survival. The same association
was found for marked lymphocytic infiltration in gastric and
rectal cancer (Yu et al., 1995; Jass, 1986). The study of Yu et
al. (1995) shows clearly that a standardised, quantitative
analysis is needed, since there was high interobserver
variation. Moreover, because these parameters can only be
assessed in resected tumour specimens, they are not useful for
preoperative staging or the prediction of resectability. In the
present study, only the amount of eosinophilic infiltration
was significantly associated with metastatic/unresectable
tumours (Table II) and actual surgical procedures (Table III).
We have compared the expression of several proteins,
associated with different steps of carcinogenesis and develop-
ment of metastasis, with lymph node status, T stage, TNM
stage and with curative resectability. In univariate analysis, a
clear association was found between Rb expression and nodal
involvement. Also, in multivariate step-wise logistic regression
analysis, positive Rb expression was the only significant
prognostic factor for nodal involvement out of all the
molecular markers (RR 3.66). Alternatively, the risk of the
operation becoming palliative was predicted with an overall
accuracy of77.0% by the combination ofRb and myc. The Rb
gene is a tumour-suppressor gene, which is frequently mutated
in a wide range of human cancer types (Bartek et al., 1992;
Harbour et al., 1988; Cryns et al., 1994). Although until now
nothing has been known about altered Rb expression in gastric
cancer, decreased expression is reported to be associated with
invasion in bladder carcinoma (Cordon-Cardo et al., 1992),
whereas it had no prognostic value in breast carcinoma
(Pietilainen et al., 1995). Since Rb is a tumour-suppressor
gene, mutations leading to decrease or loss of Rb expression
are expected to be associated with an unfavourable prognosis.
However, not all Rb mutations result in the loss of
immunohistochemically detectable expression. Instead, muta-
tions that do not abolish the production ofthe Rb protein may
lead to the production of a not functional, nuclear Rb protein
(Mittnacht et al., 1991). It has been demonstrated (Xu et al.,
Table III Univariat analysis of the association between tumour characteristics and positive marker expression and the amount of infiltrates in
primary adenocarcinomas of the stomach
Markers (n = 105) Infiltrates (n=81)a
Tumour Total p53 Rb myc nm23 Ep-CAM E-Cad VFF8 VFF18 u-PA Total Lymphocytic Eosinophilic
characteristics n (%) (%) (%) (%) (%) (%) (%) (%) (%) n 1-2(%) 3(%) J(%) 2-3(%)
T stageb
Ti 17 38 53 41 24 53 53 18 85 15 16 56 44 44 56
T2 51 41 41 49 51 59 66 28 90 45 44 70 30 66 34
T3 17 35 65 47 71 77 53 33 94 21 17 82 18 71 29
T4 16 27 75 6 44 38 100 25 88 71 3 100 0 100 0
TNM stagec
I 38 34 40 45 45 50 61 28 87 33 34 59 41 50 50
II 18 47 50 44 50 72 53 25 100 40 16 94 6 69 31
III 16 19 50 56 56 75 63 15 92 42 16 62 38 69 31
IV 28 52 71 29 57 50 79 33 83 46 14 76 14 86 14
Operation
Curative 69 34 41 48 51 62 59 24 89 36 64 67 33 58 42
Palliative 36 48 78 28 47 50 81 37 90 45 17 88 12 88 12
aResection specimens were available for 81 cases. Missing cases b(n 4), C(n=5) are left out of the analysis. (%), row percentages; bold,
statistically significant difference (P<0.05); Lymphocytic and eosinophilic infiltration 1, no or few; 2, moderate; 3, marked.Prognostic factors in gastric cancer
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Table IV Univariateanalysis of the association between marker expression and median survival (post-operative deaths excluded, n = 13) and
disease-free period (DFP) after curative resection (post-operative deaths excluded)
Overall survival
Amount of infiltrate (n=68)
2 3
12
1530 +
29
1350 +
12
1530+
19
1530 +
Marker expression (n =92)
Negative Positive
34
764
49
465
37
1050 +
45
698
52
806
62
674
22
540
60
804
28
495
P-value
0.02
0.02
1
32
1350+
15
1350+
DFP-(n =54)
Amount of infiltrate (n= 54)
2 3
12
1530+
22
1350+
10
1530+
17
1530+
Marker expression (n =59)
P-value Negative Positive
0.70
0.02
0.04
0.93
0.20
0.17
0.27
0.51
0.13
39
1350 +
35
1530 +
30
1530 +
29
1530 +
22
1530 +
23
1350 +
43
1530 +
6
1530 +
29
1530 +
19
1530 +
24
1050 +
29
1530
30
1350 +
37
1530 +
35
1530 +
11
1350 +
43
1350 +
16
1530 +
P-value
0.17
0.01
P-value
0.09
0.07
0.74
0.82
0.32
0.88
0.72
0.72
0.76
Eosinophils and lymphocytes 1, no or few; 2, moderate 3, marked.
Table V Results of stepwise Cox's regression analysis on survival (n =64, post-operative deaths excluded) and on disease-free
period (n =53, curative resections and post-operative deaths excluded)
Selected parameters n RR 95% CI P-value
Survival
Dead 31 TNM stage 1+11 42 1.00
Alive 33 III + IV 22 5.24 2.49- 11.02 <0.001
Lymphocytes No or moderate 45 1.00
Marked 19 0.21 0.07-0.63 0.004
Disease-free period
Relapse free 33 TNM stage I+II 40 1.00
Relapse 20 III+IV 13 5.62 2.13- 14.85 <0.001
Lymphocytes No or moderate 36 1.00
Marked 17 0.12 0.03-0.56 0.006
Included parameters are TNM stage, eosinophils, lymphocytes, p53, Rb, myc, nm23, Ep-CAM and E-cadherin
1991) that the staining intensity is correlated with the cell cycle
(higher in active cells). In our study, we have not analysed
whether expression is related to mutations in the Rb gene, but
it is conceivable that up-regulation, amplification or even
longer half-life of the mutant Rb protein may result in
immunohistochemically detectable overexpression of the Rb
protein. Expression of myc is related to the cell cycle and
determines either continuous proliferation or apoptosis
(Wyllie, 1993). Myc has a high turnover rate, which makes
its place as a suitable prognostic marker for routine purposes
questionable. This explains the contradictory findings that
were reported in studies of myc expression (Ninomiya et al.,
1991; Auguste et al., 1992; Borg et al., 1992; Fox et al., 1993).
Furthermore, the interpretation of the staining pattern is
highly variable. For instance, in the study of Ninomiya et al.
(1991), it is not clear what criteria were used to call a tumour
positive. In our study, the expression of CD44 splice variants
v5 and v6 was contradictory with an earlier report (Heider et
al., 1993), for unknown reasons, whereas the findings with u-
PA were similar to earlier reports (Nekarda et al., 1994).
In univariate analysis, we found that moderate and
marked eosinophilic infiltration, marked lymphocytic infiltra-
tion, Rb and myc expression had a prognostic value for
overall survival. Moderate eosinophilic infiltration was just as
favourable as marked eosinophilic infiltration, whereas only
marked lymphocytic infiltration had a strong association with
longer survival. Since there is a correlation between the
presence of lymphocytic and eosinophilic infiltrates, these two
parameters had no additional value to each other. In
multivariate step-wise Cox's regression analysis for both
overall survival and DFP, the best prognostic information
was provided by TNM stage and lymphocytic infiltrate
(Table V). TNM stage is the most important prognostic
factor for survival and also for DFP. The presence of marked
lymphocytic infiltrate was the only parameter with an
additional prognostic value to the TNM stage, while none
of the markers had an additional prognostic value.
In conclusion, a prognostic significance of the tumour
biological marker Rb was demonstrated in a large series of
gastric cancer patients. Adding also post-operatively obtained
information, lymphocytic and eosinophilic infiltrates proved
to be important prognostic markers for surgical procedure in
patients with gastric cancer. The presence and amount of
these infiltrates should, therefore, be added to other post-
operatively determinable prognostic factors in gastric cancer.
To establish reproducibility and the place of tumour markers
(n)
days
(n)
days
1
44
782
20
763
Infiltrates
Eosinophils
Median
Lymphocytes
Median
Markers
p53
Median
Rb
Median
myc
Median
nm23
Median
Ep-CAM
Median
E-cad
Median
VVF8
Median
VFF18
Median
u-PA
Median
(n)
(days)
(n)
(days)
(n)
(days)
(n)
(days)
(n)
(days)
(n)
(days)
(n)
(days)
(n)
(days)
(n)
(days)
55
835
43
1350+
55
477
47
825
40
720
29
1100
59
900 +
7
1300 +
45
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as clinical prognostic factors in patients with gastric cancer,
we have started further investigations in the tissue specimens
of the remaining patients entered in the DGCT.
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